What have we learned from the REPRIEVE trial and where do we go from here?
Publication
, Journal Article
Grinspoon, SK; Lu, MT; Zanni, MV; Diggs, MR; Chu, SM; Ribaudo, HJ; Douglas, PS
Published in: HIV Med
December 2024
Duke Scholars
Published In
HIV Med
DOI
EISSN
1468-1293
Publication Date
December 2024
Volume
25
Issue
12
Start / End Page
1283 / 1288
Location
England
Related Subject Headings
- Virology
- 4202 Epidemiology
- 3202 Clinical sciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Grinspoon, S. K., Lu, M. T., Zanni, M. V., Diggs, M. R., Chu, S. M., Ribaudo, H. J., & Douglas, P. S. (2024). What have we learned from the REPRIEVE trial and where do we go from here? HIV Med, 25(12), 1283–1288. https://doi.org/10.1111/hiv.13703
Grinspoon, Steven K., Michael T. Lu, Markella V. Zanni, Marissa R. Diggs, Sarah M. Chu, Heather J. Ribaudo, and Pamela S. Douglas. “What have we learned from the REPRIEVE trial and where do we go from here?” HIV Med 25, no. 12 (December 2024): 1283–88. https://doi.org/10.1111/hiv.13703.
Grinspoon SK, Lu MT, Zanni MV, Diggs MR, Chu SM, Ribaudo HJ, et al. What have we learned from the REPRIEVE trial and where do we go from here? HIV Med. 2024 Dec;25(12):1283–8.
Grinspoon, Steven K., et al. “What have we learned from the REPRIEVE trial and where do we go from here?” HIV Med, vol. 25, no. 12, Dec. 2024, pp. 1283–88. Pubmed, doi:10.1111/hiv.13703.
Grinspoon SK, Lu MT, Zanni MV, Diggs MR, Chu SM, Ribaudo HJ, Douglas PS. What have we learned from the REPRIEVE trial and where do we go from here? HIV Med. 2024 Dec;25(12):1283–1288.
Published In
HIV Med
DOI
EISSN
1468-1293
Publication Date
December 2024
Volume
25
Issue
12
Start / End Page
1283 / 1288
Location
England
Related Subject Headings
- Virology
- 4202 Epidemiology
- 3202 Clinical sciences
- 1103 Clinical Sciences